Development of Paroxetine Hydrochloride Single Layer Controlled-Release Tablets Based on 3<sup>2</sup> Factorial Design
Major depressive disorder (MDD) is one of the main contributors to disability and suicide mortality globally. Paroxetine hydrochloride (PHH) is the most potent antidepressant used for MDD treatment. Due to its reduced side effects PAXIL<sup>®</sup> CR is a widely-used controlled...
Main Authors: | Yao Yang, Zhengwei Huang, Xuan Zhang, Jinyuan Li, Ying Huang, Wanxin Chen, Xin Pan, Chuanbin Wu |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2018-11-01
|
Series: | Pharmaceutics |
Subjects: | |
Online Access: | https://www.mdpi.com/1999-4923/10/4/243 |
Similar Items
-
Development and Characterization of Eudragit<sup>®</sup>-Based Electrospun Nanofibrous Mats and Their Formulation into Nanofiber Tablets for the Modified Release of Furosemide
by: Marilena Vlachou, et al.
Published: (2019-09-01) -
Enhancing the Low Oral Bioavailability of Sulpiride via Fast Orally Disintegrating Tablets: Formulation, Optimization and In Vivo Characterization
by: Hesham M. Tawfeek, et al.
Published: (2020-12-01) -
Blockage of Autophagic Flux and Induction of Mitochondria Fragmentation by Paroxetine Hydrochloride in Lung Cancer Cells Promotes Apoptosis via the ROS-MAPK Pathway
by: Kun Wang, et al.
Published: (2020-01-01) -
An Improved Passive CR-39-Based Ddirect <sup>222</sup>Rn/<sup>220</sup>Rn Progeny Detector
by: Jun Hu, et al.
Published: (2020-11-01) -
Role of Intracellular Na<sup>+</sup> in the Regulation of [Ca<sup>2+</sup>]<sub>i</sub> in the Rat Suprachiasmatic Nucleus Neurons
by: Ruo-Ciao Cheng, et al.
Published: (2019-09-01)